Karvezide

irbesartan / hydrochlorothiazide

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Karvezide. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Karvezide.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

What is Karvezide?

Karvezide is a medicine that contains two active substances, irbesartan and hydrochlorothiazide. It is available as tablets (150 mg or 300 mg irbesartan and 12.5 mg hydrochlorothiazide; 300 mg irbesartan and 25 mg hydrochlorothiazide).

What is Karvezide used for?

Karvezide is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by irbesartan or hydrochlorothiazide alone. ‘Essential’ means that the hypertension has no obvious cause.

The medicine can only be obtained with a prescription.

How is Karvezide used?

The dose of Karvezide to be used depends on the dose of irbesartan or hydrochlorothiazide that the patient was taking before. Doses higher than 300 mg irbesartan and 25 mg hydrochlorothiazide once a day are not recommended. Karvezide may be added to some other treatments for hypertension.

How does Karvezide work?

Karvezide contains two active substances, irbesartan and hydrochlorothiazide.

Irbesartan is an ‘angiotensin-II-receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, irbesartan stops the hormone having an effect, allowing the blood vessels to widen.

Hydrochlorothiazide is a diuretic, which is another type of treatment for hypertension. It works by increasing urine output, reducing the amount of fluid in the blood and lowering the blood pressure.

The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone. By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.

How has Karvezide been studied?

Irbesartan on its own has been approved in the European Union (EU) since 1997 under the names Karvea and Aprovel. It can be used with hydrochlorothiazide to treat hypertension. The studies of Karvea / Aprovel used with hydrochlorothiazide as separate tablets were used to support the use of Karvezide. Further studies were also carried out with doses of 300 mg irbesartan in combination with 25 mg hydrochlorothiazide. The main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats).

What benefit has Karvezide shown during the studies?

Karvezide was more effective than placebo (a dummy treatment) and than hydrochlorothiazide alone in reducing diastolic blood pressure. Increasing the dose to 300 mg irbesartan and 25 mg hydrochlorothiazide may give a further decrease in blood pressure.

What is the risk associated with Karvezide?

The most common side effects with Karvezide (seen in between 1 and 10 patients in 100) are dizziness, nausea (feeling sick) or vomiting, abnormal urination, fatigue (tiredness), and increases in blood urea nitrogen (BUN, a breakdown product of protein), creatinine (a breakdown product of muscle) and creatine kinase (an enzyme found in muscles). For the full list of all side effects reported with Karvezide, see the package leaflet.

Karvezide must not be used in people who are hypersensitive (allergic) to irbesartan, hydrochlorothiazide, sulfonamides, or any of the other ingredients. It must not be used in women who are more than three months pregnant. Its use during the first three months of pregnancy is not recommended. Karvezide must also not be used in patients who have severe liver, kidney or bile problems, blood potassium levels that are too low or blood calcium levels that are too high. Karvezide in combination with aliskiren-containing medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment. 

Care must be taken when using Karvezide with other medicines that have an effect on blood potassium levels. The full list of these medicines is given in the package leaflet.

Why has Karvezide been approved?

The CHMP decided that Karvezide’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Other information about Karvezide

The European Commission granted a marketing authorisation valid throughout the EU for Karvezide on 16 October 1998.

Name Language First published Last updated
Karvezide : EPAR - Summary for the public BG = bălgarski 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public ES = español 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public CS = čeština 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public DA = dansk 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public DE = Deutsch 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public ET = eesti keel 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public EL = elliniká 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public EN = English 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public FR = français 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public IT = italiano 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public LV = latviešu valoda 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public LT = lietuvių kalba 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public HU = magyar 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public MT = Malti 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public NL = Nederlands 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public PL = polski 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public PT = português 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public RO = română 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public SK = slovenčina 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public SL = slovenščina 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public FI = suomi 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public SV = svenska 05/05/2009 24/09/2013
Karvezide : EPAR - Summary for the public HR = Hrvatski 05/05/2009 24/09/2013

This EPAR was last updated on 16/05/2014 .

Authorisation details

Product details

Product details for Karvezide
NameKarvezide
Agency product numberEMEA/H/C/000221
Active substance

irbesartan / hydrochlorothiazide

International non-proprietary name (INN) or common name

irbesartan / hydrochlorothiazide

Therapeutic area Hypertension
Anatomical therapeutic chemical (ATC) code C09DA04

Publication details

Publication details for Karvezide
Marketing-authorisation holder

Sanofi-aventis groupe

Revision30
Date of issue of marketing authorisation valid throughout the European Union16/10/1998

Contact address:

Sanofi-aventis groupe
54 rue La Boétie
75008 Paris
France

Product information

Product information

19/02/2014  Karvezide -EMEA/H/C/000221 -N/0168

Name Language First published Last updated
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014
Karvezide : EPAR - Product Information HR = Hrvatski 19/10/2009 16/05/2014

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  
Karvezide : EPAR - All Authorised presentations HR = Hrvatski 17/04/2007  

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Treatment of essential hypertension.

This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).

Assessment History

Changes since initial authorisation of medicine

Initial marketing-authorisation documents

Name Language First published Last updated
Karvezide : EPAR - Procedural steps taken before authorisation HR = Hrvatski 16/10/2006  
Karvezide : EPAR - Scientific Discussion HR = Hrvatski 16/10/2006  

Authorised

This medicine is approved for use in the European Union

More information on Karvezide